NLX-266 is a biased agonist of the serotonin 5-HT1A receptor. It acts specifically as a very-high-affinity and selective ERK1/2-biased serotonin 5-HT1A receptor agonist (Ki = 0.0447 nM; EC50Tooltip half-maximal effective concentration = 0.437 nM; EmaxTooltip maximal efficacy = 94%), with selectivity for ERK1/2 signaling over multiple other pathways. The drug produces antidepressant- and antiparkinsonian-like effects in rodents, with much greater efficacy than certain other serotonin 5-HT1A receptor agonists like buspirone and gepirone. It shows favorable pharmacokinetics in rodents. The chemical synthesis of NLX-266 has been described. NLX-266 was developed by Neurolixis. It was first described in the scientific literature in 2025.
See also NLX-101 (F-15599) Befiradol (NLX-112; F-13640) NLX-204 TMU4142
References